Clinical Trials Sponsored by Sankyo Pharma Gmbh

Total 378 results

Sankyo Pharma Gmbh

Completed

Olmesartan as an add-on to Amlodipine in Hypertension

Essential Hypertension

Germany
Sankyo Pharma Gmbh

Completed

Efficacy and Safety of Pactimibe in Patients With Atherosclerosis

Atherosclerosis

Germany
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Atherosclerosis

Essential Hypertension | Atherosclerotic Cardiovascular Disease

Germany
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Sankyo Pharma Gmbh

Completed

Amlodipine as add-on to Olmesartan in Hypertension

Essential Hypertension

Germany
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Hypertension and Renal Impairment

Renal Impairment | Essential Hypertension

Germany
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Deutschland GmbH

Completed

Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENCOURAGE-AF)

Non-valvular Atrial Fibrillation

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Hypertension

Spain
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Hypercholesterolemia | Mixed Dyslipidemia

Austria, United Kingdom, Italy, Germany, Belgium
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (ETNA-VTE)

Venous Thromboembolism

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI)

Atrial Fibrillation

Italy, Netherlands, Spain, Korea, Republic of, Portugal, Hungary, Serbia, United Kingdom, Germany, Belgium, Taiwan, Austria, Switzerland, France, Ukraine, Lithuania, Poland, Romania
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (ELIMINATE-AF)

Atrial Fibrillation

Spain, Belgium, Korea, Republic of, United Kingdom, Germany, Italy, Taiwan, Hungary, Czechia, Canada, Poland
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

The Confirmatory Olmesartan Plaque Regression Study (CONFIRM)

Essential Hypertension | Carotid Plaque

Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
UNICANCER
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Active, not recruiting

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis (DAISY)

Breast Tumors

France
BIT Pharma GmbH
NeuroScios GmbH; Data Magik Limited; Pharm-Analyt Labor GmbH

Completed

A Safety and Efficacy Study of NicaPlant® in Aneurysmal Subarachnoid Haemorrhage Patients Undergoing Aneurysm Clipping

Aneurysmal Subarachnoid Hemorrhage

Austria, Germany
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH; Prolytic GmbH; pharm-analyt GmbH

Completed

Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays

Allergic Rhinitis

Germany
Croma-Pharma GmbH
Proinnovera GmbH

Completed

THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit (TIMI)

Mid Face Volume Deficit

Austria
Croma-Pharma GmbH
Proinnovera GmbH

Not yet recruiting

THIODERM ELATE for Volume Augmentation in Lips (TIVOLI)

Lip; Anomaly

Austria
Croma-Pharma GmbH
Proinnovera GmbH

Active, not recruiting

THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips (TILI)

Lip Abnormality

Austria
Heidelberg University
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Unknown

Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Patients With Acute Coronary Syndrome

Germany
Menarini Group
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Hypertension

Poland, Germany, Israel, Romania, Italy, Denmark, Czechia, Croatia
zr Pharma & GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
zr Pharma & GmbH

Completed

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Neoplasms

United Kingdom, Poland, Slovakia
Pari Pharma GmbH

Completed

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

Rhinosinusitis | Chronic Polyposis

Germany
Croma-Pharma GmbH

Completed

Princess® RICH for the Correction of Fine Lines (RICH)

Lateral Canthal Lines | Perioral Rhytids

Austria
Croma-Pharma GmbH

Completed

Study of Etafill in Patients With Cataract Surgery Via the Anterior Chamber

Cataract Surgery

Austria
Croma-Pharma GmbH

Completed

Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber

Cataract Surgery

Austria
Croma-Pharma GmbH

Completed

Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars (FLASH2)

Facial Lipoatrophy | Morphological Asymmetry of the Face | Debilitating Scars

Austria
Croma-Pharma GmbH

Completed

Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds (FINO)

Correction of Nasolabial Folds

Austria
Croma-Pharma GmbH

Completed

Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars (FLASH 1)

Facial Lipoatrophy | Morphological Asymmetry of the Face | Debilitating Scars

Austria
Pari Pharma GmbH

Terminated

Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)

Bronchiolitis Obliterans

Germany
Gebro Pharma GmbH

Completed

Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee

Osteoarthritis of the Hip or Knee

Austria
Gebro Pharma GmbH

Completed

S(+)-Ibuprofen Effects on Asprin Treated Volunteers

Drug Interactions

Austria
Mika Pharma GmbH

Completed

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I

Osteoarthritis

United States
U3 Pharma GmbH

Completed

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States

Clinical Trials Sponsored by Sankyo Pharma Gmbh

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations